PM
MIST icon

Prosight Management’s Milestone Pharmaceuticals MIST Stock Holding History

Prosight Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-41,592
Closed -$77K – 59
2020
Q1 		$77K Buy
41,592
+3,111
+8% +$53.9K 0.04% 44
2019
Q4 		$616K Buy
+38,481
New +$681K 0.27% 36

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Prosight Management's MIST Position: Q2 2020 in Review

Prosight Management sold out of Milestone Pharmaceuticals (MIST) in Q2 2020, closing a stake of 41,592 shares — an estimated $77K sold.

Prosight Management first reported a position in MIST in Q4 2019 and held it in 2 quarters. The position peaked at $616K in Q4 2019. 24 funds tracked by Wall St. Rank hold MIST as of Q2 2020.

  • Prosight Management reported no remaining Milestone Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Prosight Management sold 41,592 Milestone Pharmaceuticals shares in Q2 2020, an estimated $77K.
  • Prosight Management first reported a position in Milestone Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Prosight Management's Milestone Pharmaceuticals position peaked at $616K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2020.

Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.